BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Lenvatinib
1
AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma
12/27/2025 2:50:52 AM | Browse: 104 | Download: 381
2
Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after lenvatinib therapy
12/19/2025 10:39:42 AM | Browse: 163 | Download: 437
3
Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma
11/27/2025 7:53:56 AM | Browse: 93 | Download: 477
4
Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib
11/14/2025 12:56:25 AM | Browse: 94 | Download: 451
5
Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy
8/7/2025 6:39:58 AM | Browse: 230 | Download: 548
6
Pathological complete response in advanced intrahepatic cholangiocarcinoma was achieved through tri-modal therapy: A case report and review of literature
7/14/2025 12:55:54 PM | Browse: 207 | Download: 599
7
Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus
6/20/2025 8:05:12 AM | Browse: 136 | Download: 1157
8
Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
6/13/2025 1:39:35 PM | Browse: 233 | Download: 758
9
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy
2/26/2025 4:21:32 AM | Browse: 248 | Download: 643
10
Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report
2/24/2025 9:25:50 AM | Browse: 194 | Download: 710
11
CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma
1/20/2025 7:38:49 AM | Browse: 153 | Download: 740
12
Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma
12/12/2024 9:30:58 AM | Browse: 160 | Download: 877
13
Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?
11/12/2024 12:23:36 PM | Browse: 215 | Download: 635
14
Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma
10/25/2024 10:27:34 AM | Browse: 221 | Download: 728
15
Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy
9/26/2024 10:17:46 AM | Browse: 151 | Download: 596
16
Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach
9/26/2024 10:17:46 AM | Browse: 177 | Download: 574
17
Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy
9/26/2024 8:22:28 AM | Browse: 234 | Download: 825
18
Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
7/12/2024 3:55:58 PM | Browse: 236 | Download: 586
19
Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy
6/15/2024 2:49:03 AM | Browse: 297 | Download: 1192
20
Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of literature
4/11/2024 2:23:40 AM | Browse: 228 | Download: 927
21
Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
4/11/2024 2:23:39 AM | Browse: 275 | Download: 899
22
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
2/26/2024 1:28:46 PM | Browse: 332 | Download: 1031
23
Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma
1/11/2024 5:28:09 AM | Browse: 438 | Download: 1376
24
Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
11/15/2023 1:46:53 PM | Browse: 432 | Download: 1395
25
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
3/10/2023 7:29:15 AM | Browse: 487 | Download: 1535
26
Systemic treatment for unresectable hepatocellular carcinoma
3/10/2023 7:29:15 AM | Browse: 430 | Download: 1178
27
Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review
7/14/2022 8:05:03 AM | Browse: 843 | Download: 2187
28
Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment
7/13/2022 7:31:00 AM | Browse: 624 | Download: 1920
29
Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report
4/8/2022 12:06:55 PM | Browse: 709 | Download: 1890
30
Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report
3/25/2022 2:25:11 PM | Browse: 605 | Download: 2014
31
Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
12/14/2021 11:58:13 PM | Browse: 567 | Download: 1724
32
Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
12/14/2021 11:58:13 PM | Browse: 639 | Download: 1975
33
Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
9/18/2021 1:32:04 PM | Browse: 675 | Download: 1696
34
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
5/13/2021 10:05:39 AM | Browse: 934 | Download: 2088
35
Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report
4/20/2021 12:49:51 PM | Browse: 895 | Download: 1655
36
Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report
3/20/2021 2:13:53 AM | Browse: 807 | Download: 1980
37
Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report
12/18/2020 5:58:43 AM | Browse: 860 | Download: 1732
38
Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
8/14/2020 12:33:31 PM | Browse: 1279 | Download: 3300
39
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
6/24/2020 7:33:17 AM | Browse: 961 | Download: 2126
40
Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma
5/20/2019 9:05:36 AM | Browse: 1035 | Download: 2442
41
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
2/21/2019 9:31:55 AM | Browse: 1439 | Download: 1820
42
Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
5/15/2018 7:28:22 AM | Browse: 1556 | Download: 1987
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.